RNF186 regulates glucose metabolism across multiple tissues in MAFLD, notably by playing a dual role in modulating the transcription and translocation of GLUT4 in skeletal muscle. These findings suggest that targeting the expression of RNF186 could be a potential therapeutic strategy for treating MAFLD and related metabolic disorders.
Qizhang Du (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: